Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleA new study has linked weight loss drugs, specifically GLP-1 agonists such as Mounjaro, Ozempic, and Wegovy, to an increased risk of hair loss. The research, which analysed data from approximately 50,000 people, found that GLP-1 drugs were associated with a 37 per cent to 68 per cent higher risk of alopecia compared to other diabetes medications. Regulatory bodies, including the UK's MHRA and the US FDA, have received hundreds of reports of hair loss related to these drugs, with the FDA currently evaluating this as a potential safety signal. Published in the British Medical Journal, the study suggests the hair loss is typically non-scarring alopecia, indicating that hair follicles remain intact. Researchers propose that rapid weight loss, reduced caloric intake and associated physiological stress or micronutrient deficiencies are the most likely mechanisms contributing to the hair loss. In fullWeight loss drugs linked to loss of hair in major new studyMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Weight loss drugs tied to unexpected side effect, study finds
Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleA new study has linked weight loss drugs, specifically GLP-1 agonists such as Mounjaro, Ozempic, and Wegovy, to an increased risk of hair loss. The research, which analysed data from approximately 50,000 people, found that GLP-1 drugs were associated with a 37 per cent to 68 per cent higher risk of alopecia compared to other diabetes medications. Regulatory bodies, including the UK's MHRA and the US FDA, have received hundreds of reports of hair loss related to these drugs, with the FDA currently evaluating this as a potential safety signal. Published in the British Medical Journal, the study suggests the hair loss is typically non-scarring alopecia, indicating that hair follicles remain intact. Researchers propose that rapid weight loss, reduced caloric intake and associated physiological stress or micronutrient deficiencies are the most likely mechanisms contributing to the hair loss. In fullWeight loss drugs linked to loss of hair in major new studyMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
